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58 > 31 %, conduct disorder: 19 > 7 %. At follow-up, mood- 
and anxiety disorders were virtually non-existent following 
strict criteria (1–3 %). Percentage of children having had 
pharmacological treatment at any time increased from 79 to 
91 %. On the Children’s Global Assessment Scale, 48.5 % 
of participants were still functionally impaired at follow-
up. Parental ADHD, higher ADHD symptom severity at 
baseline and higher parent-reported impairment at base-
line positively predicted current ADHD symptom severity 
(R2 = 20.9 %). Younger baseline age, higher ADHD symp-
tom severity at baseline and higher parent-reported impair-
ment at baseline were positively associated with poorer 
overall functioning (R2 = 17.8 %). Pharmacological treat-
ment had no (beneficial) impact on either ADHD symptom 
severity or overall functioning. Results confirm that ADHD 
is largely persistent into late adolescence with severity and 
family history for the disorder as important risk factors.
Abstract There are very few studies on the long-term 
outcome of children and adolescents with ADHD-com-
bined type in Europe. The objective of the present study is 
to assess the 6-year outcome (including pharmacological 
treatment) of a large cohort of participants with ADHD-
combined type (N = 347, mean age 11.4 years) in late ado-
lescence and early adulthood. At study entry and follow-up 
(mean age 17.4 years), participants were comprehensively 
assessed on ADHD and comorbid disorders by structured 
psychiatric interviews and multi-informant questionnaires. 
Overall functioning was assessed by the Children’s Global 
Assessment Scale. The retention rate was 75.6 %. The 
majority of participants (86.5 %) persisted in a DSM-5 
ADHD diagnosis, 8.4 % had a subthreshold diagnosis, and 
5.1 % remitted from the disorder at follow-up. Comor-
bidities decreased strongly; oppositional defiant disorder: 
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is char-
acterized by symptoms of inattention and/or hyperactivity/
impulsivity that lead to functional impairments in multiple 
domains [1]. Twenty longitudinal studies show an aver-
age childhood ADHD persistence rate of ~15 % at age 
25 years, although rates in individual studies vary greatly 
(4–70 %) [2]. These variable findings may be explained 
by differences in DSM versions used to diagnose ADHD, 
ADHD subtypes/severity, presence of comorbid disorders, 
ages at study entry and follow-up, adult ADHD definitions, 
and whether functional impairment was taken into account. 
A highly consistent finding is that hyperactive/impulsive 
symptoms decrease over time, and inattentive symptoms 
remain relatively stable [3, 4]. Further, persistent ADHD is 
associated with major chronic problems in adult life rela-
tive to remitted ADHD, illustrated by higher rates of sub-
stance use disorders [5] and other psychiatric comorbidities 
[6].
As symptoms of ADHD may persist in adulthood and 
are related to worse outcomes in adult life, it is of great 
clinical relevance to investigate predictors of the course 
of ADHD. Retrospective studies in large representative 
population samples report that more family adversities 
[7], greater ADHD severity [7, 8], presence of comorbidi-
ties [7], and, counter-intuitively, more treatment [7, 8] in 
childhood predict ADHD persistence, with good accuracy 
(receiver operating characteristic = 0.76 [7]). Longitudinal 
studies confirm the predictive value of family adversities 
[9, 10] and comorbidities [9], and provide some support for 
the predictive value of ADHD familiality [9, 11]. As phar-
macological treatment is currently the preferred treatment 
in ADHD, a very important question is whether continued 
pharmacological treatment is related to outcomes over time 
as well.
It is important to note that above-mentioned studies were 
limited in several ways. Most studies investigated the pre-
diction of ADHD persistence using dichotomous outcomes 
(diagnosis yes/no) [7–9], as opposed to ADHD symptom 
severity measures. Such a continuous measure may provide 
a more fine-grained picture of the disorder, and may be less 
prone to measurement errors than categorical subtypes of 
ADHD [12, 13]. Second, ADHD symptom severity might 
not convey the whole picture. An overall measure of func-
tioning based on social, psychological, and academic func-
tioning more often directly relate to the wellbeing of partic-
ipants. It may thus be highly relevant to investigate overall 
functioning as an outcome measure and so far, longitudinal 
studies assessing the prediction of overall functioning are 
scarce (but see [14]). Further, none of the longitudinal stud-
ies considered a full set of predictors together, which is 
important as predictors may overlap, having consequences 
for measures of prediction accuracy (e.g. explained vari-
ance). In addition, analyses so far yielded very limited 
sample sizes of remitters (n = 9) [9]. Another important 
caveat is that not many studies took pharmacological treat-
ment into account, which may have a significant impact on 
ADHD outcomes [15]. Finally, there are very few longitu-
dinal ADHD studies in samples outside the United States. 
Therefore, in the current study we were able to overcome 
these issues by predicting ADHD outcomes continuously, 
assessing both symptom severity and overall functioning 
in a large European cohort, assessing predictors together, 
and investigating the impact of continued pharmacological 
treatment.
An important aspect in studies looking at predictors for 
ADHD outcome is age. As significant developmental pro-
cesses (neurobiological, psychological, neurocognitive) 
of an individual are ongoing from childhood through ado-
lescence into adulthood, with a marked transition period 
in adolescence [16], predictors of ADHD outcome may 
be moderated by age. For example, higher ADHD sever-
ity may have a larger impact on adolescents compared 
to younger children, as the environment may be more 
demanding (e.g. school, jobs). So far, studies have inves-
tigated either a narrow age range, or did not specifically 
investigate effects of age. In the current study, we aimed to 
investigate children in the full range of childhood and ado-
lescence, with careful consideration of linear and quadratic 
age-dependent effects.
The main aim of the present 6-year follow-up of a large 
cohort of participants with ADHD-combined type was 
(1) to investigate outcome, i.e. ADHD persistence rates, 
comorbidity rates, symptom severity and overall function-
ing, considering age effects, (2) to investigate baseline pre-
dictors of both ADHD symptom severity and overall func-
tioning including demographics, ADHD familiality, ADHD 
severity, comorbidities and pharmacological treatment, 
considering age effects, and (3) to investigate the impact 
of continued pharmacological treatment until follow-up 
within the prediction models of ADHD symptom severity 
and overall functioning.
Methods
Participants
A sample of 347 participants with ADHD-combined type 
(ADHD/C) aged 5–19 years participated in this study. This 
sample was based on the Dutch part of the International 
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Multicenter ADHD Genetics (IMAGE) study. Between 
2003 and 2006, the IMAGE study recruited families with 
at least one child with clinically diagnosed ADHD/C and 
at least one additional sibling regardless of possible ADHD 
status. Clinical diagnosis of each participant was assessed 
by health-care professionals from clinical child care cent-
ers in The Netherlands. In addition, the diagnosis was con-
firmed, using an extensive assessment protocol described 
below. The original sample (N = 459) was contacted and 
invited for follow-up on average 6.0 years (SD = 0.7) after 
enrolment; 75.6 % (N = 347) was retained successfully.
Selection procedures have been detailed previously [17]. 
Briefly, inclusion criteria for the IMAGE study were an 
age of 5–19 years, Caucasian descent, IQ ≥70, no diagno-
sis of autism, epilepsy, general learning difficulties, brain 
disorders and known genetic disorders. Parent and teacher 
questionnaires were used to screen participants: Conners’ 
long version [18] and Strengths and Difficulties Question-
naire (SDQ [19]). T scores ≥63 on the Conners DSM-IV 
ADHD subscales Inattention (L), Hyperactivity/impulsivity 
(M), and Total symptoms (N), and scores ≥90th percentile 
on the SDQ Hyperactivity subscale were considered clini-
cal. Participants scoring clinically on any of these subscales 
were administered the Parental Account of Children’s 
Symptoms (PACS), a semi-structured, standardized, inves-
tigator-based interview with the parents as informants [20]. 
See [21] for the algorithm used to derive each of the 18 
ADHD symptoms as defined by Diagnostic and Statistical 
Manual of mental disorders: (DSM-IV-TR [1]). Only par-
ticipants with a diagnosis of ADHD/C based on the algo-
rithm at baseline were included in the current study. Partici-
pants came from 282 different families, 81.6 % was male. 
Mean age at baseline was 11.4 years (SD = 2.8) and mean 
age at follow-up was 17.4 (SD = 2.8).
Diagnostic, symptom severity and overall functioning 
assessment
At follow-up, participants were screened for ADHD using 
the Schedule for Affective Disorders and Schizophre-
nia for school-age children—present and lifetime version 
(K-SADS), a semi-structured, standardized, investigator-
based interview with the parents as informants, and when 
children were 12 years or older, also with the child (sepa-
rately) [22]. Participants with elevated scores on any of the 
screen items were administered the full ADHD interview. 
Additionally, parents completed the Conners’ Parent Rat-
ing Scale-Revised: Long version (CPRS-R:L [18]) and 
the Conners’ Teacher Rating Scale-Revised: Long ver-
sion (CTRS-R:L [23], applied for participants <18 years), 
or the Conners’ Adult ADHD Rating Scales-Self-Report: 
Long Version (CAARS-S:L [24], applied for partici-
pants ≥18 years). A diagnostic algorithm was used to 
establish ADHD status according to DSM-5 criteria, 
which was similar to the algorithm used at baseline (for 
full description of diagnostic procedures see [25]). ADHD 
subtypes (combined, inattentive, or hyperactive/impulsive 
subtype) were established following DSM-5 criteria [26]. 
Comorbidities were assessed using the PACS at baseline 
and using the K-SADS at follow-up. Classifications in both 
interviews were established according DSM-IV criteria for 
oppositional defiant disorder (ODD) and conduct disorder 
(CD). Classifications of DSM-IV anxiety-, mood-, and tic 
disorders were established in the K-SADS at follow-up.
For both the K-SADS and the PACS, interviewers 
underwent comprehensive training by a team under the 
supervision of E. Taylor at the London Institute of Psychia-
try (IoP; PACS) or JB at the Donders Institute for Brain, 
Cognition and Behavior, Radboud University Medical Cen-
tre, Nijmegen (K-SADS). If additional interviewers were 
used, each center was responsible for their training and 
supervision. Inter-rater agreement for the PACS was 0.88 
(range 0.71–1.00) and for the K-SADS 0.94 (ADHD), 0.89 
(ODD), and 0.95 (CD) [17, 25]. The interviewers were 
trained clinicians (child psychiatrists, psychologists) or 
trained researchers. Persistence of ADHD was defined as 
meeting full DSM-5 criteria of ADHD/C at baseline, and 
meeting full DSM-5 criteria of ADHD regardless of sub-
type, at follow-up. Subthreshold persistence of ADHD was 
defined as meeting full criteria of ADHD/C at baseline, 
and meeting criteria of subthreshold ADHD at follow-
up: <6 symptoms of inattention and hyperactivity/impulsiv-
ity, but ≥4 symptoms of inattention and/or hyperactivity/
impulsivity at follow-up for children <18 years. For partici-
pants ≥18 years, thresholds were five and three symptoms 
respectively. Remission of ADHD was defined as meeting 
full criteria of ADHD/C at baseline, and not meeting crite-
ria of (subthreshold) ADHD, any subtype, at follow-up.
To assess dimensional persistence, symptom change 
scores were calculated by subtracting follow-up raw scores 
from baseline raw scores on the CPRS-R:L ADHD scales 
L (Inattention), M (Hyperactivity/impulsivity), and N (Total 
symptoms) [18]. Current ADHD symptom severity, and 
inattentive and hyperactive/impulsive symptom severity 
were assessed with the follow-up raw scores on the CPRS-
R:L scales N, L and M, respectively. Scores on the Con-
ners’ ADHD subscales represent combined measures of the 
number and severity of symptoms.
To measure current overall functioning, the Global 
Assessment Scale-score of the K-SADS (K-GAS) was 
administered at follow-up. After finishing the K-SADS 
interview, the interviewer rated psychological, social and 
academic functioning, resulting in an overall measure of 
the current level of functioning ranging between 1 (worst 
possible level of functioning) and 9 (best possible level of 
functioning) [27].
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Predictors and covariates
All predictor variables were assessed at baseline. Five dif-
ferent classes (italic) were investigated. Demographic 
variables: age, sex, and socio-economic status (SES) were 
measured. SES was calculated from the average educa-
tional levels of the parent(s), with educational levels rang-
ing between 0 (no education) and 11 (university), accord-
ing to an adapted Hollingshead scale [28] fitting the Dutch 
educational system. ADHD familiality: ADHD familiality 
was investigated by measuring the percentage of siblings 
with ADHD according to the PACS interview [20], and by 
establishing current parental ADHD status, based on the 
K-SADS interview (none versus one/both parent(s) with 
ADHD). ADHD characteristics: ADHD characteristics 
included ADHD symptom severity, impairment and age 
of ADHD onset. Symptom severity was measured by the 
raw score on scale N (range 0–54) of the CPRS-R:L [18]. 
Impairment was measured using both the parent SDQ [19] 
and teacher SDQ (range 0–15) (parent and teacher ratings 
correlated r = 0.18 and were not combined). Age of onset 
of ADHD was assessed using the PACS interview [20]. 
Comorbidities: Comorbid DSM-IV defined ODD (yes/no), 
CD (yes/no) and a screening of the presence of mood/anxi-
ety symptoms (yes/no) were assessed with the PACS [29]. 
Pharmacological treatment: cumulative intake of psycho-
stimulants from age of onset until our baseline measure-
ment and from age of onset until follow-up were calculated. 
Lifetime medication transcripts from pharmacies were 
available for 87 % and covered the lifespan for 31 % of par-
ticipants. In addition, a questionnaire was administered to 
all participants and parents, which assessed lifetime history 
of psychostimulant medication. When pharmacy transcripts 
did not fully cover the self-reported treatment period, 
medication parameters of the missing period(s) were cal-
culated from the questionnaire data and were added to the 
measures derived from the pharmacy. To optimally take 
into account daily dose and duration of pharmacological 
treatment, cumulative intake was calculated by multiply-
ing the mean daily dose (average dose in milligrams for all 
exposed days; in line with prescription guidelines [30] and 
given larger direct effects of dexamphetamine on dopamin-
ergic neurotransmission [31], dexamphetamine dose was 
multiplied by 2) with treatment duration corrected for age 
(treatment duration in months divided by [age minus the 
minimum start-age within the sample, i.e., 28 months]; see 
for further details [32]).
Two potential covariates were investigated. If the univar-
iate relationship between follow-up interval and outcome 
measures was significant, follow-up interval was entered 
as a covariate in all subsequent analyses. In addition, 
study site was entered as a covariate in the final prediction 
models.
Procedure
At baseline, families were recruited from clinics and via 
advertisements. Testing took place at the VU University 
Amsterdam or at the Donders Institute in Nijmegen. Par-
ticipants were 48 h off medication during both baseline and 
follow-up assessments. All ratings of behavioral function-
ing pertained the participant’s functioning off medication. 
Families were financially compensated for participating in 
the study. Informed consent was signed by all participants 
at both measurements, and parents signed for all children 
in their family as well. The study was approved by the 
national ethics committee.
Statistical analysis
The percentage of missing data was <5 % for ADHD diag-
noses, current ADHD symptom severity and overall func-
tioning measures, 19 % for parental ADHD status, and 
between 0 and 9 % for the other predictors. Missing value 
analysis (expectation maximization) was performed for 
participants with one or two missing items on CPRS-R:L 
subscales, using all data reported in this study (scale L: 9 
participants, scale M: 18 participants). K-GAS-scores were 
normalised by applying a Van der Waerden transformation.
For our first research question, ADHD persistence 
rates, percentage of comorbidities, mean symptom change 
and overall functioning scores were calculated. It was 
tested whether symptom severity decreased significantly 
over time and whether changes in hyperactivity/impulsiv-
ity symptom severity over time differed from changes in 
inattention symptom severity. To optimally correct for the 
familial dependency in our data, Generalized Estimating 
Equation analyses (GEE) were used, with an exchangeable 
correlation structure. Additionally, interaction-effects of 
symptom change between baseline and follow-up with age/
age2 were tested. For our second research question, an opti-
mal set of predictors for current ADHD symptom severity 
and overall functioning in participants with ADHD/C was 
derived in three successive analysis steps. In step 1, GEE 
analyses were ran on each of the five classes of predictors 
separately (see Supplemental Table S1 and Supplemental 
Table S2, available online), with current ADHD symptom 
severity or overall functioning as outcome measure respec-
tively. The mean correlation between all predictors was 
0.09 (0.001 < r < 0.45), indicating no collinearity. For all 
predictors, we tested linear effects with outcome meas-
ures, except for age. Literature indicated a possible non-
linear (quadratic) relationship for the relation between age 
and our outcome measures [3]. In step 2, predictors with 
a p value <0.15 in step 1 were entered into the final GEE 
model. Finally, in step 3, a backward selection (variables 
deleted when p >0.05) procedure was performed for model 
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optimization. Additionally, to investigate possible moderat-
ing effects of age on the models for ADHD symptom sever-
ity and overall functioning, interactions between both age 
(assessed at baseline) and age2 and significant predictors 
of outcome were added to the final model. When an inter-
action-effect with age or age2 was significant, the finding 
was further explored by testing the final model in subsam-
ples subdivided based on age at baseline (<12 years and 
≥12 years). Final models were further tested separately for 
symptom severity of inattention and separately for hyperac-
tivity/impulsivity as outcome measures, to explore whether 
the model was applicable to both symptom dimensions. 
Further, as the reliability and validity of the CPRS-R:L 
is only established for children under 18 years of age, we 
tested whether results of the final model for current ADHD 
symptom severity replicated in a subsample of children 
younger than 18 years. Second, the effect of missing data 
on the final models for both outcome measures was inves-
tigated, testing the final model using only participants with 
complete data. For our third research question, the first 
three steps of our GEE model were repeated, except that 
pharmacological treatment until baseline was replaced by 
pharmacological treatment until follow-up.
Results
Attrition analysis
Attrition was investigated by comparing participants suc-
cessfully followed up (75.6 %) with participants lost to 
follow-up on variables reported in this study available at 
baseline. No significant group differences were found (0.13 
< p < 0.95).
Current ADHD‑related outcomes
Table 1 shows the descriptives at baseline and follow-up of 
ADHD diagnosis, comorbidities, symptom severity and over-
all functioning. Supplemental Table 3 shows these characteris-
tics in younger and older children (<12 years and ≥12 years). 
Of 459 children with ADHD/C at baseline, 333 children 
(72.5 %) had available information on categorical diagnoses at 
follow-up; 86.5 % of them persisted in a full ADHD diagnosis 
[51.4 % ADHD/C, 39.6 % ADHD inattentive-type (ADHD/I), 
9.0 % ADHD hyperactive/impulsive-type (ADHD/H)], 8.4 % 
had a subthreshold diagnosis, and 5.1 % remitted from the 
disorder. In younger and older children these rates were com-
parable (χ2 = 2.871, p = 0.720). Regarding comorbidities at 
baseline, ODD was apparent in 58.0 % of the participants, CD 
in 18.9 % of the participants. At follow-up, ODD was appar-
ent in 30.8 % of the participants, CD in 6.6 %, tic disorders 
(any type) in 2.1 %, mood disorders (depression or dysthymia) 
in 1.8 %, and anxiety disorders in 2.5 % of the participants. 
Regarding pharmacological treatment, at baseline, 78.8 % of 
the participants have had pharmacological treatment for their 
ADHD symptoms at any time, compared to 90.9 % of the 
participants at follow-up. At follow-up, 87.1 % of participants 
used methylphenidate (immediate release) at any time, 65.4 % 
used methylphenidate (extended release), and 6.5 % of partici-
pants used dexamphetamine.
Total raw ADHD symptom severity on the CPRS-R:L 
scale N decreased from 35.51 to 23.27 (p < 0.001, mean 
change = 12.24, SD = 11.69). Inattentive raw symptom 
severity on the CPRS-R:L scale L decreased from 18.59 to 
13.85 (p < 0.001, mean change = 4.74, SD = 6.79), and 
hyperactive/impulsive raw symptom severity on the CPRS-
R:L scale M decreased from 16.92 to 9.42 (p < 0.001, mean 
change = 7.50, SD = 6.28). The decrease in hyperactiv-
ity/impulsivity was larger than the decrease in inattention 
(p < 0.001). Interaction effects of symptom change between 
baseline and follow-up with age/age2 were significant for 
inattention (b = 0.42/0.02 and p = 0.003/0.004, respec-
tively), showing that inattentive symptoms decreased more 
in older than younger children, then leveling off around the 
age of 16–18 (age at follow-up).
Of 332 participants with current K-GAS-scores avail-
able, 161 participants (48.5 %) were functionally impaired 
at follow-up (K-GAS-score ≤6). Eight participants (2.4 %) 
had optimal functioning scores (K-GAS-score = 9). Of 
288 participants with persistent ADHD and current K-GAS 
scores available, 153 participants (53.1 %) were function-
ally impaired at follow-up. Two participants (0.7 %) with 
persistent ADHD had optimal functioning scores. Older age 
was associated with better overall functioning, as reflected 
in a higher current K-GAS-score (b = 0.09, p < 0.001).
Prediction of current ADHD symptom severity 
and overall functioning
Given our high ADHD persistence rates, prediction models 
were tested only for our dimensional measures of ADHD. 
Table 2 shows the final prediction models for current 
ADHD symptom severity. Higher current ADHD symp-
tom severity was predicted by positive parental ADHD sta-
tus, higher baseline ADHD symptom severity, and higher 
parent-reported baseline impairment, explaining 20.9 % of 
variance.
Table 3 shows the final prediction model for current 
overall functioning. Lower K-GAS-scores were predicted 
by younger age at baseline, higher baseline ADHD symp-
tom severity, and higher parent-reported baseline impair-
ment, explaining 17.8 % of variance.
For current ADHD symptom severity none of the 
predictors interacted significantly with age or age2 
(0.12 < p < 0.58). For current overall functioning, there 
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Table 1  Characteristics of children with ADHD/C at baseline and follow-up
Mean SD
Baseline
 Demographic variables
  Age (years) 11.41 2.78
  Sex (N/% male) 283 81.6
  SES (average educational level of the parents) 5.39 2.21
 ADHD familiality
  ADHD status siblings (% of siblings with ADHD) 63.55 26.01
  Parental ADHD status (N/% ADHD in one or both parents) 96 34.2
 ADHD severitya
  CPRS-R:L total symptom severity (scale N) 35.51 8.57
  CPRS-R:L inattentive symptom severity (scale L) 18.59 4.92
  CPRS-R:L hyperactive/impulsive symptom severity (scale M) 16.92 5.19
  SDQ Impairment
   Parent 12.37 3.91
   Teacher 8.03 3.17
  Age of onset first ADHD symptoms (years) 2.25 1.52
 ADHD pharmacological treatment
  Mean daily dose (milligram, unit equivalents) 13.31 12.92
  Cumulative intake of psychostimulants 53.20 73.74
 Comorbidities
  PACS ODD diagnosis (yes) 184 58.0
  PACS CD diagnosis (yes) 60 18.9
  PACS screen anxiety/depression (yes) 188 59.3
Follow-up
 Demographic variables
  Age at follow-up (years) 17.36 2.79
 ADHD severitya
  CPRS-R:L total symptom severity (scale N) 23.27 11.38
  CPRS-R:L total symptom severity change score (scale N) 12.24 11.69
  CPRS-R:L inattentive symptom severity (scale L) 13.85 6.55
  CPRS-R:L inattentive symptom severity change score (scale L) 4.74 6.79
  CPRS-R:L hyperactive/impulsive symptom severity (scale M) 9.42 5.98
  CPRS-R:L hyperactive/impulsive symptom severity change score (scale M) 7.50 6.28
 ADHD pharmacological treatment
  Mean daily dose (milligram, unit equivalents) 22.04 15.74
  Cumulative intake of psychostimulants 126.00 120.49
 Status at follow-up
  Kiddie-Global Assessment Scale at follow-up 6.42 1.14
  ADHD persistence (N/%) 288 86.5
   ADHD/C (N/%) 148 51.4
   ADHD/I (N/%) 114 40.6
   ADHD/H (N/%) 26 9.0
  Subthreshold ADHD (N/%) 28 8.4
  ADHD remitter (N/%) 17 5.1
 Comorbidities at follow-up
  ODD (N/%) 103 30.8
  CD (N/%) 22 6.6
  Tic disorder (N/%) 7 2.1
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was a significant interaction between age and parent-
reported impairment (p = 0.029). Further exploration 
showed that parent-reported impairment was a significant 
predictor of current overall functioning only in the sub-
sample of younger participants (p < 0.001) and not in the 
subsample of older participants (p = 0.64). The predic-
tion model for current ADHD symptom severity (including 
parental status of ADHD, baseline symptom severity, and 
baseline parent-reported impairment) remained significant 
(0.000 < p < 0.027) when tested for ADHD inattention 
symptom severity (R2 = 14.7 %) and ADHD hyperactivity/
impulsivity symptom severity (R2 = 20.2 %).
All predictors in the final model for current ADHD symp-
tom severity remained significant with similar relationships 
when tested in a subsample with children younger than 
18 years (0.002 < p < 0.010, R2 = 16.9 %), demonstrating that 
the findings were not the result of applying the CPRS-R:L 
in children of 18–24 years old. Findings for current ADHD 
symptom severity replicated when cases without complete 
data were removed from the analyses (0.001 < p < 0.012, 
R2 = 21.4 %). Predictors in the final model for current overall 
functioning remained significant (baseline symptom sever-
ity) or marginally significant (age, baseline parent-reported 
impairment; 0.001 < p < 0.069, R2 = 16.8 %).
Continued pharmacological treatment
To investigate whether continued pharmacological treatment 
is related to better outcomes (hypothesis 3), pharmacologi-
cal treatment until follow-up was added to the model pre-
dicting current ADHD symptom severity and overall func-
tioning. In the first model, one additional predictor was now 
significant; more continued pharmacological treatment also 
predicted higher symptom severity (b = 0.011, p = 0.020). 
The total model explained 22.5 % of variance. For overall 
functioning, continued pharmacological treatment until fol-
low-up did not contribute to the model.
Covariates
Follow-up interval was significantly related to the K-GAS-
score (b = −0.25, p = 0.001), but not to ADHD symptom 
severity (b = 1.64, p = 0.22), and therefore was added to 
the model of overall functioning as a covariate for all sub-
sequent analyses. Further, study site was a non-signifi-
cant predictor in both the final model of ADHD symptom 
severity (b = 0.22, p = 0.87) and of overall functioning 
(b = 0.10, p = 0.31). Adding this covariate to these final 
models did neither change direction of effects of predictors, 
nor their significance (p < 0.05).
Discussion
The current European prospective study investigated the 
course of ADHD/C from childhood into late adolescence/
ADHD attention-deficit/hyperactivity disorder, ADHD/C attention-deficit/hyperactivity disorder-combined type, ADHD/H attention-deficit/
hyperactivity disorder-hyperactive/impulsive type, ADHD/I attention-deficit/hyperactivity disorder-inattentive type, CD conduct disorder, CPRS-
R:L Conners’ parent rating scale-revised: Long version ODD oppositional defiant disorder, PACS parental account of children’s symptoms, SDQ 
strengths and difficulties questionnaire, SES socio-economic status
a Combined measures of parent/self and teacher report
Table 1  continued
Mean SD
  Mood disorder (N/%) 6 1.8
  Anxiety disorder (N/%) 8 2.5
Table 2  Final prediction model for current ADHD symptom severity 
in children with ADHD/C
ADHD attention-deficit/hyperactivity disorder, CPRS-R:L Conners’ 
Parent Rating Scale-Revised: long version SDQ strengths and diffi-
culties questionnaire
a Unstandardized regression coefficient
B ba SE p
Parental ADHD status 0.15 3.53 1.24 0.004
CPRS-R:L symptom severity 0.26 0.35 0.08 <0.001
SDQ parent-reported impairment 0.25 0.74 0.19 0.003
R2 = 20.89 %
Table 3  Final prediction model for the current global assessment 
scale in children with ADHD/C
ADHD attention-deficit/hyperactivity disorder, CPRS-R:L Conners’ 
Parent Rating Scale-Revised: long version SDQ strengths and diffi-
culties questionnaire
a Unstandardized regression coefficient
b Models are corrected for follow-up interval
B ba SE pb
Age at baseline 0.15 0.05 0.02 0.008
CPRS-R:L symptom severity −0.26 −0.02 0.004 <0.001
SDQ parent-reported impairment −0.15 −0.04 0.01 0.004
R2 = 17.75 %
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young adulthood and studied a full set of potential impor-
tant predictors for ADHD outcomes: current symptom 
severity and overall functioning. Importantly, the additional 
value of continued pharmacological treatment was exam-
ined. In summary, although symptom severity decreased, 
persistence rates were indisputably high: the vast major-
ity of participants had a persistent DSM-5 ADHD diag-
nosis (86.5 %), independent of age. The greater part of 
ADHD persisters still met combined type criteria (51.4 %). 
About half (48.5 %) of participants were still functionally 
impaired at follow-up [22]. At follow-up, comorbidity rates 
(ODD, CD) decreased strongly compared with the baseline 
measurement. Mood and anxiety disorders were virtually 
non-existent following strict criteria (1–3 %). The large 
majority of participants (>90 %) had taken stimulants at 
some point in time. Predictive variables together explained 
up to 20 % of variance in our outcome measures: higher 
ADHD symptom severity and higher parent-reported 
impairment predicted higher current ADHD symptom 
severity and lower overall functioning. Positive parental 
ADHD status contributed to the prediction of higher cur-
rent ADHD symptom severity, while being younger at ini-
tial participation predicted lower overall functioning. Age 
further was important as a moderator in the prediction of 
overall functioning: parent-reported impairment was pre-
dictive only in younger children (<12 years). Continued 
pharmacological treatment was of no relevance for overall 
functioning at follow-up, and against our expectation, phar-
macological treatment was positively related to symptom 
severity at follow-up.
As noted above, ADHD symptom severity decreased 
significantly, but symptom decrease was only slight, and 
many adolescents and young adults still fulfilled criteria for 
a DSM-classification. Although this prospect was expected 
for the younger part of our sample, a striking finding is that 
persistence rates were similarly high in the older part of the 
sample (age up to 25). An important explanation may be 
our stringent inclusion criteria applied at baseline: ADHD-
combined criteria had to be met by all participants, a sub-
type that was found highly predictive of a persistent course 
[7]. Adolescents still meeting full criteria for ADHD/C 
may be considered as relatively more severely affected 
compared to younger children meeting these criteria. This 
may have resulted in one of the highest reported persis-
tence rates thus far; even higher than the 70 % persistence 
rate that was found in the Langley study [10]. The rate of 
mood and anxiety disorders at follow-up in our sample is 
lower compared to most other studies [33]. It is possible 
that participants with higher rates of mood or anxiety dis-
orders were less willing to participate at follow-up. How-
ever, there were no differences in comorbidity measures at 
baseline between participants successfully followed-up or 
participants lost to follow-up, making this suggestion less 
likely. Possibly, comorbid problems in ADHD emerge early 
in childhood and may remit during adolescence, which 
is what our findings regarding the decrease of ODD and 
CD rates suggest. For mood disorders, this idea was sup-
ported by a study of Biederman and colleagues, showing 
that comorbid rates of mood disorders in participants with 
ADHD in adulthood seem comparable to those in a control 
group, regardless of higher levels of mood disorders ear-
lier in life in participants with ADHD [34]. For both mood 
and anxiety disorders, another explanation may (also) hold 
true. Comparing our results with similar studies that used 
strict DSM-IV criteria with both parents and participants as 
informants, an important difference is that we considered a 
disorder present when it was apparent at the time of assess-
ment, while other studies used wider time-intervals, e.g. 
considering a disorder present when apparent within the 
past 3–5 years [9, 34].
Our study clearly confirms that ADHD/C is a strongly 
pervasive disorder at least until adolescence/young adult-
hood. The relative stability of ADHD symptoms is espe-
cially important given that the adolescent brain develops 
strongly during the transition from puberty into adulthood, 
marked by increased reward seeking activities leading to 
problematic decision-making processes [16]. In combi-
nation with ongoing symptoms of ADHD, this may have 
unfavorable effects on academic, health, and social out-
comes, and may lead to adverse outcomes such as offend-
ing behavior. On the other hand, offering a more positive 
perspective, comorbidity rates decreased strongly and 
about half of our sample was not severely impaired, but had 
a moderate level of overall functioning.
Current symptoms and overall functioning were pre-
dicted by a few variables only, which together explained up 
to 20 % of variance. Not surprisingly, having many symp-
toms and being highly impaired at baseline predict worse 
future outcomes, which was also reported by other [9, 35], 
but not all, studies [11]. The positive predictive value of 
parental ADHD for current symptom severity is consistent 
with studies showing that broader concepts as ‘family his-
tory of ADHD’ or ‘parental psychopathology’ are related 
to ADHD outcomes [9, 10]. This finding may be attributed 
to genetic factors, but it is also possible that this predic-
tive effect relates to family-environmental factors. As we 
have shown, parental status of ADHD is a more impor-
tant predictor than having siblings with ADHD. Given that 
siblings and parents share a comparable genetic make-up 
with the proband, and siblings usually have less influence 
on upbringing than their parents, our finding may indicate 
an important role for family-environmental factors in the 
course of ADHD. Finally, younger age at baseline predicted 
lower overall functioning as well as higher ADHD severity, 
but the latter only in combination with continued pharma-
cological treatment. An explanation for this finding is that 
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the world is expanding more for older children compared 
to younger children. The impact of symptom severity may 
be relatively smaller then, or may add positively to overall 
functioning as risk taking behaviour may increase, which 
can be interesting for peers on that age.
Interestingly, our prediction models for ADHD out-
comes were largely independent of the developmental 
phase of participants, confirming the stability of our predic-
tors in a sample of children with ADHD/C with a large age 
range. Only for current overall functioning parent-reported 
impairment was a significant predictor in younger children, 
which may be explained by the smaller involvement of par-
ents when children grow older, with a decrease in correct 
judgement of impairment levels of their child accordingly.
Cumulative intake of psychostimulant medication nei-
ther at baseline nor at follow-up had a beneficial impact 
on ADHD outcomes or overall functioning in our sample. 
Moreover, higher cumulative intake at follow-up predicted 
worse outcomes in terms of ADHD severity. Although 
ADHD symptoms have been shown to decrease with stimu-
lant treatment, our findings do not support long-term posi-
tive effects on outcome. Three other studies also found that 
ADHD treatment (any type) positively predicted ADHD 
persistence [8, 36], or ADHD severity [10], which was 
interpreted as treatment being a proxy of ADHD severity. 
This explanation may also underlie our current finding. 
In line with this, the results of the Multimodal Treatment 
study of ADHD (MTA), a large randomized controlled 
trial comparing the effects of systematic pharmacological 
treatment, behavioral therapy, a combination of these two, 
or usual community care, suggested that initial benefits of 
pharmacological treatment on cognitive functioning and 
symptom severity dissipated from 2 years on [35]. Accord-
ingly, a recent study showed that when psychostimulant 
medication intake increased in a population of children 
with ADHD, there were no positive effects on functional 
outcome measures such as academic outcomes or schooling 
attainment [37]. Conversely, evidence for negative effects 
on mood and non-serious adverse events (e.g. sleeping 
problems, decreased appetite) were evident [37, 38], indi-
cating that, in line with our findings, the long-term effects 
of pharmacological treatment on functional outcomes of 
ADHD may need reconsideration [39].
Although we were able to explain a moderate amount of 
variance in current symptom severity and overall function-
ing, many of the baseline predictor variables were unrelated 
to outcomes including sex, SES, age of onset, and comor-
bidities. As we investigated sets of predictors together, it 
may be that comorbidities were not included in the model 
as they may overlap with ADHD symptom severity meas-
ures. Indeed, ODD was related to ADHD symptom sever-
ity in the separate class analyses but did not retain in the 
model with other predictor variables. Two other studies 
showed a somewhat larger role for the predictive value 
of CD [9, 40]. The first study showed that comorbid CD 
at baseline was significantly more often seen in ADHD 
persisters or late remitters (after the age of 12 years) com-
pared to participants that remitted from the disorder before 
the age of 12 years [9]. In the second study, childhood CD 
as a comorbid condition predicted failure to graduate and 
young parenthood compared to ADHD childhood CD [40]. 
The discrepancies between these two studies and our find-
ings regarding the predictive value of comorbid CD may be 
explained by a variety of factors: e.g. the use of different 
definitions or operationalization of dependent and outcome 
measures, including different samples or using a different 
statistical or methodological approach. Further, one study 
showed that comorbidities were predictive of persistence 
when using a combined measure [7], indicating that a 
measure of ‘general vulnerability’ for developing persisting 
disorders may be of importance. For the other non-signifi-
cant predictors, our findings are in line with the current lit-
erature [7–9, 11].
Limitations and future recommendations
Although we studied a relatively large sample of partici-
pants with ADHD/C compared to other studies, the sample 
may have been relatively small for our analyses including 
interaction-effects with age. Second, including partici-
pants with other types of ADHD (such as ADHD/I) would 
have allowed us to investigate whether these subtypes 
showed higher remittance rates than ADHD/C. Further, 
participants were all of Caucasian origin, limiting gener-
alisation to a broader ethnic population. Fourth, interview-
ers were not systematically blinded for diagnostic status 
when administering diagnostic interviews. However, since 
both families and interviewers had no specific interest 
in the outcome measures in our study, we don’t consider 
this a major bias in the results. Fifth, different diagnostic 
interviews were used at baseline (PACS) and at follow-up 
(K-SADS). As both interviews systematically investigated 
similar DSM criteria for ADHD, we do not expect this dif-
ference to have a major impact on our results. Finally, our 
study was restricted to children with a clinical diagnosis, 
whereas some previous studies recruited participants with 
ADHD symptoms from the general population [6, 41] who 
may be less severely affected, resulting in higher remission 
rates. Also, it should be of note that persistence rates may 
decrease more with older age in adulthood [6].
As the majority of variance in ADHD outcomes remain 
unexplained, far more studies are warranted for a more 
accurate prediction of future ADHD outcomes. For exam-
ple, studies should include other variables that relate to 
family-environmental factors, such as upbringing style 
or attachment style. Perhaps multiple domains can be 
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integrated in one model, by also including genetic varia-
tions, structural and functional brain measures, and neuro-
cognitive factors [42–45].
Conclusion
Our study demonstrates that combined type ADHD 
strongly persists into late adolescence and young adult-
hood, posing a challenge for adolescence and adult mental 
health care as problems do not disappear. Risk factors for 
worse outcomes in adolescence or young adulthood include 
high ADHD symptom severity and impairment, younger 
age, parental ADHD, and more continued pharmacologi-
cal treatment. The developmental phase of participants was 
of little importance for our predictors for ADHD outcome, 
showing the importance of these predictors for the entire 
ADHD sample. In an era in which pharmacological treat-
ment is the preferred type of intervention, our finding that 
pharmacological treatment had no positive predictive value 
for ADHD-related outcomes is clinically important and 
substantiates further study into this topic. Finally, it is of 
great relevance for future work to discover the factors that 
cover the 80 % unexplained variance of our models that 
predict future outcome, to give direction to develop newer 
and potentially more effective interventions.
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